Telix half year revenue increases 22 per cent to 477 million dollars
Radiopharmaceutical manufacturer Telix Pharmaceuticals reported 477 million dollars in half year group revenue on 20 August 2026 boosting gross margin to 55 per cent
Telix Pharmaceuticals Limited reported a 22% increase in revenue for the first half of 2026, reaching US$477 million. The company's gross margin improved by 2% year-over-year to 55%, while its Precision Medicine gross margin increased by 1% to 65%. Adjusted EBITDA rose by 146% year-over-year to US$52 million, driven by strong demand across Telix's product portfolio and initial payments from a collaboration with Regeneron.
The company invested US$124 million in research and development, primarily focused on advancing late-stage therapeutic and precision medicine programs. Telix also entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies. The company refinanced its convertible bond structure, issuing US$600 million of new convertible bonds due in 2031.
CEO Dr. Christian Behrenbruch highlighted Telix's strong revenue growth, market share gains, and progress in clinical and regulatory milestones, entering the second half with confidence. Telix's Precision Medicine segment saw a 27% year-over-year increase in revenue, with Illuccix and Gozellix delivering growth in sales volumes and market share.
The company is also advancing several key late-stage development programs in its Therapeutics business.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
